Merck
MRK
About: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Employees: 75,000
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
3% more call options, than puts
Call options by funds: $2.52B | Put options by funds: $2.44B
0.92% more ownership
Funds ownership: 76.91% [Q1] → 77.83% (+0.92%) [Q2]
4% less funds holding
Funds holding: 3,400 [Q1] → 3,269 (-131) [Q2]
12% less capital invested
Capital invested by funds: $177B [Q1] → $155B (-$21.9B) [Q2]
16% less repeat investments, than reductions
Existing positions increased: 1,268 | Existing positions reduced: 1,513
28% less first-time investments, than exits
New positions opened: 181 | Existing positions closed: 251
34% less funds holding in top 10
Funds holding in top 10: 64 [Q1] → 42 (-22) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Berenberg
Luisa Hector
|
$90
|
Hold
Downgraded
|
17 Sep 2025 |
|
Wells Fargo
Mohit Bansal
|
$90
|
Equal-Weight
Maintained
|
30 Jul 2025 |
|
Morgan Stanley
Terence Flynn
|
$98
|
Equal-Weight
Maintained
|
10 Jul 2025 |
Financial journalist opinion
Based on 43 articles about MRK published over the past 30 days
